Existing and upcoming small molecules in psoriasis treatment
Small molecules as PDE4, JAK, and TYK2 are emerging as potential new treatment targets for psoriasis. Trials suggest comparable efficacy as high potency steroid in some types of psoriasis, but without the commonly known side effects. The possibility to produce topical and oral formulars is another main advantage of small molecules. Eniko Sonkoly, MD, associate professor in Dermatology, guides you through the promising results of phase II/III clinical trials for oral treatment with TYK2 inhibitors and topical treatment with aryl hydrocarbon receptor agonists.
Få tillgång till artikeln
Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.